Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer
Integra LifeSciences (NASDAQ: IART) has appointed Mojdeh Poul as its new president and CEO, effective January 6, 2025. Poul, who previously served as executive vice president and group president of 3M's $8.5B Global Healthcare Business, will succeed Jan De Witte. She brings extensive experience in healthcare business strategy, portfolio transformation, and commercial operations. Poul's background includes leadership positions at Medtronic and Boston Scientific, and she currently serves on the boards of Align Technology, iRhythm Technologies, and Stanley Black & Decker. Stuart Essig will temporarily serve as executive chairman before returning to his non-executive chairman role.
Integra LifeSciences (NASDAQ: IART) ha nominato Mojdeh Poul come nuovo presidente e amministratore delegato, con effetto dal 6 gennaio 2025. Poul, che in precedenza ha ricoperto il ruolo di vicepresidente esecutivo e presidente del gruppo nella divisione sanitaria globale di 3M, del valore di 8,5 miliardi di dollari, succederà a Jan De Witte. Porta con sé una vasta esperienza nella strategia commerciale nel settore sanitario, nella trasformazione del portafoglio e nelle operazioni commerciali. Il suo percorso professionale include ruoli dirigenziali in Medtronic e Boston Scientific, e attualmente fa parte dei consigli di amministrazione di Align Technology, iRhythm Technologies e Stanley Black & Decker. Stuart Essig assumerà temporaneamente il ruolo di presidente esecutivo prima di tornare al suo ruolo di presidente non esecutivo.
Integra LifeSciences (NASDAQ: IART) ha nombrado a Mojdeh Poul como su nueva presidenta y CEO, con efecto a partir del 6 de enero de 2025. Poul, quien anteriormente se desempeñó como vicepresidenta ejecutiva y presidenta del grupo en el negocio de atención médica global de 3M, de 8.5 mil millones de dólares, sucederá a Jan De Witte. Aporta una amplia experiencia en la estrategia empresarial de atención médica, transformación de portafolios y operaciones comerciales. La trayectoria de Poul incluye posiciones de liderazgo en Medtronic y Boston Scientific, y actualmente forma parte de las juntas de Align Technology, iRhythm Technologies y Stanley Black & Decker. Stuart Essig servirá temporalmente como presidente ejecutivo antes de regresar a su rol de presidente no ejecutivo.
Integra LifeSciences (NASDAQ: IART)은 Mojdeh Poul을 2025년 1월 6일부터 새로운 회장 겸 CEO로 임명했습니다. Poul은 이전에 3M의 85억 달러 규모 글로벌 헬스케어 비즈니스의 수석 부사장 겸 그룹 회장으로 재직했으며, Jan De Witte의 후임이 됩니다. 그녀는 헬스케어 비즈니스 전략, 포트폴리오 전환 및 상업 운영 분야에서 광범위한 경험을 보유하고 있습니다. Poul의 경력에는 Medtronic과 Boston Scientific의 리더십 직위가 포함되며, 현재 Align Technology, iRhythm Technologies 및 Stanley Black & Decker의 이사회에서도 활동하고 있습니다. Stuart Essig은 비상임 회장 역할로 돌아가기 전에 임시로 사내 의장직을 맡게 됩니다.
Integra LifeSciences (NASDAQ: IART) a nommé Mojdeh Poul en tant que nouvelle présidente et PDG, prenant effet le 6 janvier 2025. Poul, qui a précédemment été vice-présidente exécutive et présidente du groupe du secteur de la santé mondial de 3M, d'une valeur de 8,5 milliards de dollars, succédera à Jan De Witte. Elle apporte une vaste expérience dans la stratégie commerciale de la santé, la transformation de portefeuille et les opérations commerciales. Le parcours de Poul inclut des postes de direction chez Medtronic et Boston Scientific, et elle siège actuellement aux conseils d'administration d'Align Technology, iRhythm Technologies et Stanley Black & Decker. Stuart Essig occupera temporairement le poste de président exécutif avant de revenir à son rôle de président non exécutif.
Integra LifeSciences (NASDAQ: IART) hat Mojdeh Poul als neue Präsidentin und CEO ernannt, die am 6. Januar 2025 ihre Tätigkeit aufnehmen wird. Poul, die zuvor als Executive Vice President und Gruppenleiterin des globalen Gesundheitsgeschäfts von 3M mit einem Volumen von 8,5 Milliarden USD tätig war, wird Jan De Witte nachfolgen. Sie bringt umfangreiche Erfahrung in der Unternehmensstrategie im Gesundheitswesen, der Portfoliotransformation und dem kommerziellen Betrieb mit. Poul war in Führungspositionen bei Medtronic und Boston Scientific tätig und ist derzeit Mitglied der Vorstände von Align Technology, iRhythm Technologies und Stanley Black & Decker. Stuart Essig wird vorübergehend als Executive Chairman fungieren, bevor er zu seiner Rolle als nicht-executive Chairman zurückkehrt.
- Appointment of experienced healthcare executive with proven track record in managing $8.5B business
- New CEO brings expertise in strategic acquisitions and portfolio transformation
- Strong background in advanced wound care, relevant to Integra's core business
- Extensive board experience with major technology companies
- Leadership transition period could create temporary operational uncertainty
- Multiple board commitments of new CEO might affect focus on Integra
A proven healthcare executive with deep global expertise and a distinguished record in business strategy and execution, portfolio transformation, value-creating innovation, commercial excellence, and leadership development
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced that its board of directors has appointed Mojdeh Poul as the new president and chief executive officer, effective January 6, 2025. Ms. Poul will also join the Integra board when she assumes the role. She will succeed Jan De Witte, who will remain president and CEO until January 6, 2025. Stuart Essig will remain executive chairman of Integra for a limited period of time before returning to his prior role as non-executive chairman.
“The board and I are thrilled to welcome Mojdeh as Integra’s next president and CEO,” said Stuart Essig, executive chairman of Integra. “Mojdeh is a seasoned global healthcare executive who brings a wealth of knowledge and expertise in business strategy and transformation, commercial excellence, and leadership development. Her passion for building high-performance teams that navigate complexity and deliver results will be critical in driving and successfully executing our strategic and operational plans. Mojdeh’s proven track record in advancing the vision and leadership impact of the companies she has served gives me great confidence she will successfully lead Integra in its mission to set new standards of care.”
Most recently, Ms. Poul was the executive vice president and group president for 3M’s
“I am honored to serve as the next president and CEO of Integra and thankful to Stuart and the board for their trust in my leadership,” said Ms. Poul. “As we work through the transition, we will remain sharply focused on executing our operational and quality compliance strategic priorities, while maximizing the potential of Integra’s leading product portfolio. I look forward to partnering with the board and working with our teams and customers to advance our products and technologies to restore patients’ lives.”
Ms. Poul currently serves on the board of directors and is a member of the audit committee at Align Technology. She is also a board director and member of the audit committee at iRhythm Technologies, as well as a board director and member of the audit, and the compensation and talent development committees at Stanley Black and Decker.
Ms. Poul received her bachelor’s and master’s degrees in mechanical engineering from the University of Louisville. She also holds an MBA from the University of North Carolina at Chapel Hill.
Mr. Essig added, “We want to thank Jan for his leadership and contributions to Integra, many of which lay the groundwork for future success. His focus on growing our international business, integrating digital technology into our product pipeline, attracting top talent and building strong, capable teams will leave a lasting impact on Integra. In addition, Jan shaped our portfolio through the strategic acquisitions of Surgical Innovation Associates, the makers of Durasorb®, and Acclarent. We also appreciate Jan’s leadership in driving our operational and quality compliance strategic plans and his commitment to facilitating a smooth leadership transition.”
“I want to express my sincerest gratitude to our dedicated and talented Integra colleagues for their resilience and determination over the years and their unwavering commitment to our mission to help customers and patients,” said Mr. De Witte. “Integra has been a pioneer in medical innovations for 35 years and I believe its portfolio of technological advancements and its people, whose passion and commitment to our purpose and values, are instrumental to Integra’s success, now and well into the future.”
About Integra LifeSciences
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands. For the latest news and information about Integra and its products, please visit www.integralife.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements. These forward-looking statements relate to, among other things, expectations, estimates and projections concerning the Company’s business and operations, financial performance, strategic initiatives, resources, product development and regulatory approvals, and the leadership transition. Forward-looking statements in this news release should be evaluated together with the many risks and uncertainties that affect Integra’s business and market which include but are not limited to: the ability of the Company to successfully manage leadership changes, other factors beyond the Company's control and the economic, competitive, governmental, technological, and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2023, and information contained in subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Contacts:
Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/06e1a69c-ec6f-4dd3-8493-2859560dbdea
FAQ
When will Mojdeh Poul start as CEO of Integra LifeSciences (IART)?
What was Mojdeh Poul's previous position before joining Integra LifeSciences (IART)?
Who is Mojdeh Poul replacing as CEO at Integra LifeSciences (IART)?
What other board positions does Mojdeh Poul currently hold besides Integra (IART)?
